Global Cancer Diagnostics Grants First International License for The Lung Cancer Test™ to Bertech Pharma Ltd.

The Lung Cancer Test is Proven to Screen High Risk Patient Populations for the Early Detection of Lung Cancer and will Soon Be Available in Canada

 Global Cancer Diagnostics

PHOENIX, Jan. 8, 2015 /PRNewswire/ — Global Cancer Diagnostics Inc. announced the signing of a license agreement with Bertech Diagnostics Ltd. of Edmonton, Alberta. This agreement enables Bertech to sell The Lung Cancer Test™ in Canada. With this partnership, The Lung Cancer Test™ will continue its rapid expansion for use by current and former smokers. The Lung Cancer Test™ was introduced to the U.S. marketplace in late 2014.

The Lung Cancer Test™ is recommended for annual screening for Lung Cancer in current and former smokers. The Test has been clinically proven to detect Lung Cancer in its early stages. With early detection comes early treatment and higher survival rates.

Bertech is addressing the need for patient-friendly, accurate and inexpensive diagnostic tests in Canada. They are located in Edmonton, Canada and will utilize partnerships with laboratories throughout Canada to provide the test. The Lung Cancer Test™ will be a complement to Bertech’s line of colorectal cancer diagnostics and treatments. Information on The Lung Cancer Test™ in Canada can be obtained by contacting Bertech at (780) 988-1515.

More information in the U.S. can be obtained at or by calling the Global Cancer Diagnostics laboratory at (602) 908-9604. The website provides information on lung cancer, how the test works, along with corporate management bios.

All required Clinical and Validation studies have been completed with excellent results. The Test detects the presence of the required biomarkers that are proven effective in the early detection of lung cancer. The Test is now available in all U.S. states.  The Lung Cancer Test™ is intended for use in the high-risk patient population, which includes current and former smokers over the age of 50. Global Cancer Diagnostics Inc. announced that The Lung Cancer Test™ was available for purchase beginning late last year.

In additional news, the Company will be attending the J.P. Morgan Healthcare Conference in San Francisco, January 13 – 15. This is considered to be the largest and most informative healthcare investment symposium in the industry, which brings together global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. They expect more than 300 companies, both public and private, to deliver presentations to more than 4,000 investors.  Global Cancer Diagnostics is meeting with companies to discuss national and international partnerships and licensing.

About Lung Cancer

Lung cancer is the most fatal of cancers, taking an estimated 158,000 lives annually in the U.S. alone. Lung cancer is the leading cause of cancer death among both men and women – only 16.6% of those diagnosed in Stages 3 and 4 will live beyond 5 years. Only 15% of cases are diagnosed at an early stage using X-Ray and CT Scan. Smoking causes 80 to 90% of lung cancer deaths. By detecting lung cancer in Stages 1 and 2, the survival rate increases to more than 80%.  The CDC estimated in 2010 that there were 43.5 million smokers in the U.S. and that the number of former smokers exceeded the number of current smokers.

About Global Cancer Diagnostics Inc.

Global Cancer Diagnostics is a privately owned, Biotechnology Company with an in-house CLIA certified diagnostic laboratory. The Company is located in Tempe, Arizona USA. The Company provides the scientific and operating management resources to have introduced its novel diagnostic technology in the domestic and global marketplace. For more information, visit the company’s Web site at

About Bertech Diagnostics Ltd:

Bertech Diagnostics Ltd. (“Bertech”) is a privately held biotechnology company located inEdmonton, Canada.  Bertech and its affiliated enterprises (“The Bertech Group”) develop and distribute innovative, leading edge tools for the diagnosis and treatment of cancer.

In addition to ensuring the Canadian market has access to Global Cancer Diagnostic’s innovative The Lung Cancer Test™, Bertech currently has in development a novel blood test for the diagnosis of colorectal cancer, an ELISA assay for monitoring a patient’s immune response to colorectal cancer treatments, along with several new cancer compounds which are in preclinical development. These compounds are structurally divergent from established drugs, are devoid of the genotoxic properties of many contemporary anti-cancer drugs, and will reverse multi-drug resistance.

For additional information, please contact Mr. Bern Philip, President & CEO, at 1-780-988-1515 or email

Global Cancer Diagnostics Inc.
William Gartner, President & CEO

Don Roberton, VP & COO

Posted in AZBio News.